高糖对糖尿病肾病（DN）的危害一直是研究者关注的重点，然而体内广泛存在的核糖与其之间的关系却未引起重视。我们临床发现2型糖尿病（DM）患者尿核糖水平较健康人群显著升高，研究证实核糖能够迅速与蛋白质发生非酶促糖基化，生成具有明显细胞毒性的糖基化终末产物，给予小鼠口服核糖可引起肾脏病理改变。中药降糖复方是本课题组治疗DM临床常用方，研究证实该方可有效降低2型DM患者及DN小鼠尿白蛋白和尿核糖水平。基于此我们提出假说，即核糖代谢异常可能是DN的重要致病因素之一，中药降糖复方治疗该病的作用可能与调节核糖代谢有关。本课题拟通过动物及细胞实验，阐明核糖代谢异常在DN发病中的作用，并鉴定与核糖糖基化相关的蛋白；同时探究该复方是否以调节核糖代谢为靶点发挥其治疗DN的作用。本项目不仅能阐明核糖代谢异常对DN的影响机制，还能明确中药降糖复方对核糖代谢的作用，有望在指导临床应用的同时为DN的研究开启一条新途径。

Diabetic Nephropathy（DN）is one of diseases which are harmful to human beings. The influence of high glucose on DN has always been the focus of researchers, while the relationship between D-ribose and DN takes rear attention.Our prophase researches have proved that the cytotoxic advanced glycation end produces(AGEs) were produced by glycation between the D-ribose and protein. as their producets, which is. Renal pathological changes are found when ribose is given to mice by oral administration, what’s more, clinical trials have showed the level of D-ribose is significantly higher in patients with type 2 diabetes mellitus (T2DM) comparing to healthy groups.Chinese herbal compound for reduce blood gluscose (ZYJTFF) is a prescription commonly used to treat DM , with obvious effect in reducing the level of uriary albumin and D-ribose.Based on these, we propose that ZYJTFF may treat DN by controlling D-ribose metabolism, the abnormal of which can be a determining pathogenic factor in DN.In this study, animal and cell experiments are used to discover the influence of abnormal D-ribose metabolism on DN and identify the protein that is closely related to glycosylation of D-ribose. All these may contribute to the answer of whether ZYJTFF treats DN by targeting at controlling D-ribose metabolism. The study can not only clarify the intervention mechanism of abnormal ribose metabolism on DN, but also confirm the effect of ZYJTFF on ribose metabolism. All these may contribute to a guidance in clinical application and a new way for DN research.